Nanoliposomal Irinotecan
1 clinical trials · Condition
◉ Watch Nanoliposomal Irinotecan
| Record | Firm | Date |
|---|---|---|
| NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC (NCT06405490) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-04-17 |
Track Nanoliposomal Irinotecan automatically
Every clearance here is in the API, with alerts when new ones post.